References
Kornhauser T, Schwartz R, Goldstein M, Neudorfer M, Lowenstein A, Barak A (2015) Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up). Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-01-3130-z
Epstein DLJ, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119:1184–1189
Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049
Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL (2014) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion. The rubeosis and-VEGF (RAVE) trial. Retina 34:1728–1735
Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86
Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A (2014) Lont-term outcomes in patients with retinal vein occlusion treated with ranibizumab. The RETAIN study. Ophthalmology 121:209–219
Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. Two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420
Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion. 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158:1032–1038
Călugăru M (1987) Les resultats d’une enquete sur la survenue du glaucome neovasculaire après occlusion de la veine centrale de la retine. J Fr Ophtalmol 10:479–483
Chan A, Duker JS, Ko T, Fujimoto JG, Schuman JS (2006) Normal macular thickness measurements in healthy eyes using status optical coherence tomography. Arch Ophthalmol 124:193–198
Acknowledgments
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest, and have no financial disclosures to report. Both authors (D.C. and M.C.) were involved in the design and conduct of the study, the collection, management, analysis and interpretation of the data, and the preparation, review and approval of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors have full control of the primary data and have agreed to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request.
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Rights and permissions
About this article
Cite this article
Călugăru, D., Călugăru, M. Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up (BERVOLT study: bevacizumab for RVO long-term follow-up). Graefes Arch Clin Exp Ophthalmol 254, 1023–1024 (2016). https://doi.org/10.1007/s00417-015-3219-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-015-3219-4